

Freedom of Information Act 2000 - Request Reference Fol/21/385

Treatments for Schizophrenia

Q1. In the past 6 months, how many patients has your trust treated [for any condition] with the following drugs:

- Aripiprazole long-acting injectable (Abilify Maintena)
- Olanzapine pamoate (Zypadhera)
- Paliperidone palmitate, once monthly (Xeplion)
- Paliperidone palmitate, three monthly (Trevicta)
- Risperidone long-acting injectable (Risperdal Consta)
- Flupentixol decanoate (Depixol)
- Fluphenazine decanoate (Modecate)
- Haloperidol decanoate (Haldol Decanoate)
- Pipotiazine palmitate (Piportil)
- Zuclopenthixol decanoate (Clopixol)

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

Q2. Within your organisation how many patients are currently [within the past 6 months] being treated for Schizophrenia (ICD code: F20)

125*

*Please note that these are the figures for those coded with Schizophrenia on discharge from an Inpatient admission or Daycase/RDA Attendance and will not include patients currently in hospital or those treated in an Outpatient or Community setting.

Q3. Of the Schizophrenia patients ONLY, how many are currently [within the past 6 months] being treated with the following drugs:

- **Aripiprazole long-acting injectable (Abilify Maintena)**
- **Olanzapine pamoate (Zypadhera)**
- **Paliperidone palmitate, once monthly (Xeplion)**
- **Paliperidone palmitate, three monthly (Trevicta)**
- **Risperidone long-acting injectable (Risperdal Consta)**
- **Flupentixol decanoate (Depixol)**
- **Fluphenazine decanoate (Modecate)**
- **Haloperidol decanoate (Haldol Decanoate)**
- **Pipotiazine palmitate (Piportil)**
- **Zuclopenthixol decanoate (Clopixol)**

Please see Question 1.